Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02646982 · ClinicalTrials.gov registry record · Phase 2
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
A Phase 2 study of Mild Cognitive Impairment, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
- 2
- Study locations
NCT02646982 is a Phase 2 study of Mild Cognitive Impairment that has completed, run by Emory University. The registered enrollment target is 77 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02646982, a Phase 2 study of Mild Cognitive Impairment, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease biomarkers.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Candesartan
Study Locations (2)
Georgia
- Emory University - Atlanta
- Wesley Woods Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2020-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02646982
The ClinicalTrials.gov registry entry for NCT02646982 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (94% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02646982 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02646982 about?
NCT02646982 is a clinical study titled "Candesartan's Effects on Alzheimer's Disease And Related Biomarkers". This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease biomarkers.
What is the current status of trial NCT02646982?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2016-06-30. Estimated completion is 2020-08-17.
What conditions does trial NCT02646982 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
What interventions are being tested in trial NCT02646982?
The interventions under investigation include: Placebo (DRUG), Candesartan (DRUG).
Who is sponsoring clinical trial NCT02646982?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02646982 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
RECRUITING · Phase 2
-
The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study
RECRUITING · Phase 2
-
Rapamycin - Effects on Alzheimer's and Cognitive Health
RECRUITING · Phase 2
-
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
RECRUITING · Phase 2
-
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.